Main Article Content
In this article, the authors described and commented the main provisions of the new guidelines for the examination and treatment of patients with amiodarone-associated thyroid dysfunction. Their text is divided thematically into subdivisions (clinical studies, diagnosis, approaches to the management). At the same time, the text with references is presented first that followed by guidelines, which are given according to the level of evidence.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
Tanda ML, Piantanida E, Lai A, et al. Diagnosis and management of amiodarone-induced thyrotoxicosis: similarities and differences between North American and European thyroidologists. Clin Endocrinol (Oxf). 2008 Nov;69(5):812-8. doi: 10.1111/j.1365-2265.2008.03268.x.
Ahmed S, Van Gelder IC, Wiesfeld ACP, Van Veldhuisen DJ, Links TP. Determinants and outcome of amiodarone-associated thyroid dysfunction. Clin Endocrinol (Oxf). 2011 Sep;75(3):388-94. doi: 10.1111/j.1365-2265.2011.04087.x.
Swiglo BA, Murad MH, Schunemann HJ, et al. A case for clarity, consistency and helpfulness: State-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. J Clin Endocrinol Metab. 2008 Mar;93(3):666-73. doi: 10.1210/jc.2007-1907.
Lambert MJ, Burger AG, Galeazzi RL, Engler D. Are selective increases in serum thyroxine (T4) due to iodinated inhibitors of T4 monodeiodination indicative of hyperthyroidism? J Clin Endocrinol Metab. 1982 Dec;55(6):1058-65. doi: 10.1210/jcem-55-6-1058.
Nademanee K, Singh BN, Callahan B, Hendrickson JA, Hershman JM. Amiodarone, thyroid indexes, and altered thyroid function: long-term serial effects in patients with cardiac arrhythmias. Am J Cardiol. 1986 Nov 1;58(10):981-6.
Yamazaki K, Mitsuhashi T, Yamada E, et al. Amiodarone reversibly decreases sodium-iodide symporter mRNA expression at therapeutic concentrations and induces antioxidant responses at supraphysiological concentrations in cultured human thyroid follicles. Thyroid. 2007 Dec;17(12):1189-200. doi: 10.1089/thy.2007.0215.
Melmed S, Nademanee K, Reed AW, Hendrickson JA, Singh BN, Hershman JM. Hyperthyroxinemia with bradycardia and normal thyrotropin secretion after chronic amiodarone administration. J Clin Endocrinol Metab. 1981 Nov;53(5):997-1001. doi: 10.1210/jcem-53-5-997.
Batcher EL, Tang XC, Singh BN, Singh SN, Reda DJ, Hershman JM; SAFE-T Investigatorsю Thyroid function abnormalities during amiodarone therapy for persistent atrial fibrillation. Am J Med. 2007 Oct;120(10):880-5. doi: 10.1016/j.amjmed.2007.04.022.
Zhong B, Wang Y, Zhang G, Wang Z. Environmental iodine content, female sex and age are associated with new-onset amiodarone-induced hypothyroidism: a systematic review and meta-analysis of adverse reactions of amiodarone on the thyroid. Cardiology. 2016;134(3):366-71. doi: 10.1159/000444578.
Benjamens S, Dullaart RPF, Sluiter WJ, Rienstra M, van Gelder IC, Links TP. The clinical value of regular thyroid function tests during amiodarone treatment. Eur J Endocrinol. 2017 Jul;177(1):9-14. doi: 10.1530/EJE-17-0018.
Bartalena L, Bogazzi F, Braverman LE, Martino E. Effects of amiodarone administration during pregnancy on neonatal thyroid function and subsequent neurodevelopment. J Endocrinol Invest. 2001 Feb;24(2):116-30. doi: 10.1007/BF03343825.
Theodoraki A, Vanderpump MPJ. Thyrotoxicosis associated with the use of amiodarone: the utility of ultrasound in patient management. Clin Endocrinol (Oxf). 2016; 84(2):172-176. doi: 10.1111/cen.12988.
Bogazzi F, Bartalena L, Dell’Unto E, et al. Proportion of type 1 and type 2 amiodarone-induced thyrotoxicosis has changed over a 27-year period in Italy. Clin Endocrinol (Oxf). 2007 Oct;67(4):533-7. doi: 10.1111/j.1365-2265.2007.02920.x.
Balzano S, Sau F, Bartalena L, et al. Diagnosis of amiodarone-iodine-induced thyrotoxicosis (AIIT) associated with severe nonthyroidal illness. Clin Endocrinol (Oxf). 2007 Oct;67(4):533-7. doi: 10.1111/j.1365-2265.2007.02920.x.
Tomisti L, Urbani C, Rossi G, et al. The presence of anti-thyroglobulin (TgAb) and/or anti-thyroperoxidase antibodies (TPOAb) does not exclude the diagnosis of type 2 amiodarone-induced thyrotoxicosis. J Endocrinol Invest. 2016 May;39(5):585-91. doi: 10.1007/s40618-015-0426-0.
Piga M, Cocco MC, Serra A, Boi F, Loy M, Mariotti S. The usefulness of 99mTc-sestaMIBI thyroid scan in the differential diagnosis and management of amiodarone-induced thyrotoxicosis. Eur J Endocrinol. 2008 Oct;159(4):423-9. doi: 10.1530/EJE-08-0348.
Pattison DA, Westcott J, Lichtenstein M, et al. Quantitative assessment of thyroid-to-background ratio improves the interobserver reliability of technetium-99m sestamibi thyroid scintigraphy for investigation of amiodarone-induced thyrotoxicosis. Nucl Med Commun. 2015 Apr;36(4):356-62. doi: 10.1097/MNM.0000000000000260.
Loy M, Perra E, Melis A, et al. Color-flow Doppler sonography in the differential diagnosis and management of amiodarone-induced thyrotoxicosis. Acta Radiol. 2007 Jul;48(6):628-34. doi: 10.1080/02841850701342138.
O’Sullivan AJ, Lewis M, Diamond T. Amiodarone-induced thyrotoxicosis: left ventricular dysfunction is associated with increased mortality. Eur J Endocrinol. 2006 Apr;154(4):533-6. doi: 10.1530/eje.1.02122.
Wang TJ, Evans JC, Benjamin EJ, Levy D, LeRoy EC, Vasan RS. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation. 2003 Aug 26;108(8):977-82. doi: 10.1161/01.CIR.0000085166.44904.79.
Tomisti L, Del Re M, Bartalena L, et al. Effects of amiodarone, thyroid hormones and CYP2C9 and VKORC1 polymorphisms on warfarin metabolism: a review of the literature. Endocr Pract. 2013 Nov-Dec;19(6):1043-9. doi: 10.4158/EP13093.RA.
Tomisti L, Materazzi G, Bartalena L, et al. Total thyroidectomy in patients with amiodarone-induced thyrotoxicosis and severe left ventricular systolic dysfunction. J Clin Endocrinol Metab. 2012 Oct;97(10):3515-21. doi: 10.1210/jc.2012-1797.
Pierret C, Tourtier JP, Pons Y, Merat S, Duverger V, Perrier E. Total thyroidectomy for amiodarone-associated thyrotoxicosis: should surgery always be delayed for pre-operative medical preparation? J Laryngol Otol. 2012 Jul;126(7):701-5. doi: 10.1017/S0022215112000722.
Kaderli RM, Fahrner R, Christ ER, et al. Total thyroidectomy for amiodarone-induced thyrotoxicosis in the hyperthyroid state. Exp Clin Endocrinol Diabetes. 2016 Jan;124(1):45-8. doi: 10.1055/s-0035-1565094.
Zhu L, Zainudin SB, Kaushik M, Khor LY, Chng CL. Plasma exchange in the treatment of thyroid storm secondary to type II amiodarone-induced thyrotoxicosis. Endocrinol Diabetes Metab Case Rep. 2016;2016:160039. doi: 10.1530/EDM-16-0039.
Sato K, Shiga T, Matsuda N, Onoda N, Takano K, Hagiara N, Kasanuki H. Mild and short recurrence of type II amiodarone-induced thyrotoxicosis in three patients receiving amiodarone continuously for more than 10 years. Endocr J. 2006 Aug;53(4):531-8.
Bogazzi F, Bartalena L, Tomisti L, Rossi G, Brogioni S, Martino E. Continuation of amiodarone delays restoration of euthyroidism in patients with type 2 amiodarone-induced thyrotoxicosis treated with prednisone: a pilot study . J Clin Endocrinol Metab. 2011 Nov;96(11):3374-80. doi: 10.1210/jc.2011-1678.
Bogazzi F, Tomisti L, Rossi G, et al. Glucocorticoids are preferable to thionamides as first-line treatment for amiodarone-induced thyrotoxicosis due to destructive thyroiditis: a matched retrospective cohort study. J Clin Endocrinol Metab. 2009 Oct;94(10):3757-62. doi: 10.1210/jc.2009-0940.
Bogazzi F, Bartalena L, Cosci C, et al. Treatment of type II amiodarone-induced thyrotoxicosis by either iopanoic acid or glucocorticoids: a prospective, randomized study. J Clin Endocrinol Metab. 2003 May;88(5):1999-2002. doi: 10.1210/jc.2002-021874.
Bogazzi F, Bartalena L, Tomisti L, et al. Glucocorticoid response in amiodarone-induced thyrotoxicosis resulting from destructive thyroiditis is predicted by thyroid volume and serum free thyroid hormone concentrations. J Clin Endocrinol Metab. 2007 Feb;92(2):556-62. doi: 10.1210/jc.2006-2059.
Albino CC, Paz-G, Graf H. Recombinant human TSH as an adjuvant to radioiodine for the treatment of type 1 amiodarone-induced thyrotoxicosis (AIT). Clin Endocrinol (Oxf). 2009 May;70(5):810-1. doi: 10.1111/j.1365-2265.2008.03405.x.
Bogazzi F, Tomisti L, Ceccarelli C, Martino E. Recombinant human TSH as an adjuvant to radioiodine for the treatment of type 1 amiodarone-induced thyrotoxicosis: a cautionary note. Clin Endocrinol (Oxf). 2010 Jan;72(1):133-4. doi: 10.1111/j.1365-2265.2009.03600.x.
Houghton SG, Farley DR, Brennan MD, van Heerden JA, Thompson GB, Grant CS. Surgical management of amiodarone-associated thyrotoxicosis: Mayo Clinic experience. World J Surg. 2004 Nov;28(11):1083-7. doi: 10.1007/s00268-004-7599-6.
Maqdasy S, Batisse-Lignier M, Auclair C, et al. Amiodarone-induced thyrotoxicosis recurrence after amiodarone reintroduction. Am J Cardiol. 2016 Apr 1;117(7):1112-6. doi: 10.1016/j.amjcard.2016.01.003.